Drug management of prostate cancer: Prevalence and consequences of renal insufficiency

Clinical Genitourinary Cancer

Volumn 7, Issue 3, 2009, Pages

  Launay Vacher, Vincent ^a   Ayllon, Jorge ^b   Janus, Nicolas ^a   Spano, Jean Philippe ^a   Ray Coquard, Isabelle ^c   Gligorov, Joseph ^d   Pourrat, Xavier ^e   Morere, Jean François ^f   Beuzeboc, Philippe ^g   Deray, Gilbert ^a   Oudard, Stéphane ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c CENTRE LÉON BÉRARD   (France)

^d HÔPITAL TENON   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f AVICENNE HOSPITAL   (France)

^g INSTITUT CURIE   (France)

Author keywords

Anemia; Cockcroft Gault; Dosage adjustment; IRMA; Nephrotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GOSERELIN; IRINOTECAN; LEUPRORELIN; METHOTREXATE; MITOXANTRONE; NAVELBINE; NILUTAMIDE; OXALIPLATIN; PACLITAXEL; PAMIDRONIC ACID; PIRARUBICIN; TRIPTORELIN; VINBLASTINE; ZOLEDRONIC ACID;

ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PROSTATE CANCER;

EID: 70449116208     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.029     Document Type: Article

References (17)

1. Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32:992-999
2. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007; 110:1376-1384
3. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006; 12:6258s-63s.
4. Tripathy AD, Diel I, Body JJ. Ibandronate reduces skeletal morbidity in patients with breast cancer. Semin Oncol 2004; 31(suppl 10):64-66
5. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744
6. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349:1676-1679
7. Cockcroft DW, Gault MH. Prediction of CrCl from serum creatinine. Nephron 1976; 16:31-41.
8. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11:0828.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1-266.
10. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089-2100
11. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia, PA: American College of Physicians; 1999.
12. Launay-Vacher V, Karie S, Deray G. GPR Anticancéreux: Guide de Prescription des Médicaments Chez le Patient Insuffisant Rénal. 3rd ed. Paris, France: Meditions International; 2005.
13. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005; 67:706-713 (Pubitemid 40139864)
14. Body JJ, Coleman R, Clezardin P, et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007; 43:852-858
15. Lichtman S, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007; 43:14-34. (Pubitemid 46070218)
16. Launay-Vacher V, Chatelut E, Lichtman S, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations. Ann Oncol 2007; 18:1314-1321 (Pubitemid 47305003)
17. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-432